Former BioDelivery CEO saw 31.5 percent boost in 2017 compensation
Former BioDelivery CEO Mark Sirgo saw a 31.5 percent increase in 2017 compensation.
Read More
biodelivery sciences
Pain management company BioDelivery Sciences names new CEO
RALEIGH – BioDelivery Sciences International Inc. (NASDAQ:BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine, has appointed Herm Cukier CEO and board member. Former President and CEO, Mark A. Sirgo, will continue his role as vice chair and will work with Cukier on the transition. Cukier...
Read MoreBioDelivery Sciences settles patent lawsuit with Teva
“We believe this settlement will provide additional certainty around our patent portfolio and the future potential for our two commercialized products,” says BDSI CEO Dr. Mark Sirgo.
Read MoreVeteran BDSI executive, CTO decides to retire
Veteran executive Niraj Vasisht is retiring from BioDelivery Sciences, the firm says in a regulatory filing.
Read More- 1
- 2
